CA2664165A1 - Use of mtki 1 for treating or preventing bone cancer - Google Patents

Use of mtki 1 for treating or preventing bone cancer Download PDF

Info

Publication number
CA2664165A1
CA2664165A1 CA002664165A CA2664165A CA2664165A1 CA 2664165 A1 CA2664165 A1 CA 2664165A1 CA 002664165 A CA002664165 A CA 002664165A CA 2664165 A CA2664165 A CA 2664165A CA 2664165 A1 CA2664165 A1 CA 2664165A1
Authority
CA
Canada
Prior art keywords
bone
cancer
compound
bromo
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002664165A
Other languages
English (en)
French (fr)
Inventor
Timothy Pietro Suren Perera
Michel Marie Francois Janicot
Theo Frans Meert
Eddy Jean Edgard Freyne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica Nv
Timothy Pietro Suren Perera
Michel Marie Francois Janicot
Theo Frans Meert
Eddy Jean Edgard Freyne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv, Timothy Pietro Suren Perera, Michel Marie Francois Janicot, Theo Frans Meert, Eddy Jean Edgard Freyne filed Critical Janssen Pharmaceutica Nv
Publication of CA2664165A1 publication Critical patent/CA2664165A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA002664165A 2006-10-27 2007-10-25 Use of mtki 1 for treating or preventing bone cancer Abandoned CA2664165A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US86316706P 2006-10-27 2006-10-27
EP06123060.3 2006-10-27
EP06123060 2006-10-27
US60/863,167 2006-10-27
US97618807P 2007-09-28 2007-09-28
US60/976,188 2007-09-28
PCT/EP2007/061501 WO2008049904A2 (en) 2006-10-27 2007-10-25 Use of mtki 1 for treating or preventing bone cancer

Publications (1)

Publication Number Publication Date
CA2664165A1 true CA2664165A1 (en) 2008-05-02

Family

ID=39066650

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002664165A Abandoned CA2664165A1 (en) 2006-10-27 2007-10-25 Use of mtki 1 for treating or preventing bone cancer

Country Status (11)

Country Link
EP (1) EP2101782A2 (ja)
JP (1) JP2010507628A (ja)
KR (1) KR20090086977A (ja)
AU (1) AU2007310845A1 (ja)
BR (1) BRPI0718021A2 (ja)
CA (1) CA2664165A1 (ja)
EA (1) EA200970420A1 (ja)
IL (1) IL198344A0 (ja)
MX (1) MX2009004438A (ja)
NO (1) NO20092059L (ja)
WO (1) WO2008049904A2 (ja)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8603801A1 (es) * 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv Derivados de la quinazolina
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
GB0507347D0 (en) * 2005-04-12 2005-05-18 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
NO20092059L (no) 2009-06-29
MX2009004438A (es) 2009-05-11
KR20090086977A (ko) 2009-08-14
JP2010507628A (ja) 2010-03-11
IL198344A0 (en) 2010-02-17
EA200970420A1 (ru) 2009-12-30
EP2101782A2 (en) 2009-09-23
AU2007310845A1 (en) 2008-05-02
BRPI0718021A2 (pt) 2013-11-12
WO2008049904A2 (en) 2008-05-02
WO2008049904A3 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
TWI649081B (zh) 治療固態腫瘤之方法
CA2915005C (en) Use of eribulin and lenvatinib as combination therapy for treatment of cancer
AU2015278765B2 (en) Intermittent dosing of MDM2 inhibitor
JP6761852B2 (ja) がん治療
JP2021512101A (ja) 肥満細胞症の治療のための併用療法
ES2668272T3 (es) Administración de inhibidor de enzimas que activa NEDD8 y agente de hipometilación
CA2866021C (en) Procaspace 3 activation by pac-1 combination therapy
AU2019315550A1 (en) Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof
JP2017530129A (ja) ツブリシン複合体を用いた癌の治療方法
US20090029966A1 (en) Combination therapy with parp inhibitors
RU2592230C2 (ru) Апоптоз раковой клетки
CN114364402A (zh) 用于治疗癌症的阿片类生长因子受体(ogfr)拮抗剂，特别是纳洛酮和/或纳曲酮
CA2664148A1 (en) Vegfr3 inhibitors
US20200129473A1 (en) Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer
TW202012000A (zh) 治療癌症之方法
US20080213275A1 (en) Use of mtki 1 for treating or preventing bone cancer
CA2664165A1 (en) Use of mtki 1 for treating or preventing bone cancer
de la Vega et al. Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carcinoma of the head and neck: a GICOR phase I trial
JP6810763B2 (ja) がん治療
US20080153853A1 (en) Use of mtki 1 for treating or preventing brain cancer
JP2006519209A (ja) ネモルビシン（ｎｅｍｏｒｕｂｉｃｉｎ）の肝臓内投与により肝臓癌を治療するための方法
CA3141072A1 (en) Methods and uses for treating cancer
CN101528234A (zh) Mtki1用于治疗或预防骨癌的用途
TW202339753A (zh) 用於與抗癌藥物共同投與之包含酞嗪酮衍生物之醫藥組合物
Yang Daniel T. Nagasawa, MD, Frances Chow, BA, Andrew Yew, MD, Won Kim, MD, Nicole Cremer, BS

Legal Events

Date Code Title Description
FZDE Discontinued